Medchemexpress LLC Thiazolo[5,4-f]quinazoline-2-carboximidic acid, 9-[(2-fluoro-4-methoxyphenyl)amino]-, methyl ester | 1425945-60-3 | 98.1% | 383.40 | 25 MG

Supplier:  Medchemexpress LLC 25MGHY111380

EHT 1610 is a potent and selective inhibitor of DYRK1A and DYRK1B, demonstrating antileukemia effects by inducing apoptosis and regulating the cell cycle. It targets key signaling pathways, including FOXO1, STAT3, and cyclin D3, to impact cell-cycle progression, mitochondrial ROS, and DNA damage. In vivo, EHT 1610 exhibits antileukemia activity, reducing leukemic burden and improving survival in B-ALL xenograft models. This compound is a light yellow to yellow solid and requires freshly prepared solutions due to its inherent instability.

• Potent DYRK inhibitor (DYRK1A IC50 0.36 nM, DYRK1B IC50 0.59 nM)
• Induces apoptosis in leukemic cells, including resistant ALL
• Regulates cell cycle; inhibits FOXO1, STAT3, cyclin D3 phosphorylation
• In vivo antileukemia activity and survival benefits in B-ALL models
• Light yellow to yellow solid
• Unstable in solutions; requires fresh preparation

Catalog No. 50-003-46930